Enter the e-mail address you used when you registered an account with IIR Energy.
A message will be sent to the E-Mail Address found in our records containing the associated username(s) as well as instructions for a password reset.
Indian bio-pharma major Bharat Biotech International Limited (BBIL) announced it would be manufacturing up to a billion doses of a single-dose intranasal COVID-19 vaccine in collaboration with the Washington University School of Medicine in St Louis, Missouri. According to the company, this novel chimp-adenovirus vaccine candidate - "ChAd-SARS-CoV-2-S," has shown unprecedented levels of protection in mice studies. Besides India's native COVID-19 vaccine "Covaxin," BBIL already is working on another intranasal vaccine - "Coroflu."
Phase I trials for the vaccine would take place in Saint Louis University's Vaccine and Treatment Evaluation Unit. BBIL, upon obtaining the required regulatory approval, would pursue further stages of clinical trials in India. On successful trial, BBIL would undertake large-scale manufacturing of the vaccine at its GMP facility at Genome Valley near Hyderabad city in Southern India.
Industrial Info is tracking 67 active COVID-19 related projects, worth over $393 million, in India.
|Listen to Today's News||News Audio Library||Sync News Podcasts|
This article is free for all Registered Members.
Register Now! All Fields are Required...
Upgrade your Premium News Subscription to include all archived articles for only $160. Contact Member Services: 800-762-3361
All Members Receive the Following Free Resources: